[New aspects of pharmacological effects of ursodeoxycholic acid].
The paper reviews the use of hepatoprotective agents in chronic liver diseases (CLD) and biliary disorders. A variety of clinical studies have shown the beneficial effect of ursodeoxycholic acid (UDCA) in liver disease worldwide. Besides the well-known mechanisms of action of UDCA we could show its prebiotic effect. Several studies have demonstrated that UDCA serves as a potential therapeutic agent for a number non-hepatobiliary disorders including cardiovascular disease, immune disorders, organ transplantation and other.
V G
VG
Radchenko
P V
PV
Seliverstov
S I
SI
Sitkin
D001660:Biliary Tract Diseases / Q000188:drug therapy* / Q000209:etiology; D002756:Cholagogues and Choleretics / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome; D014580:Ursodeoxycholic Acid / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
D002756:Cholagogues and Choleretics; D014580:Ursodeoxycholic Acid